Unclear boundaries between investigator-controlled and sponsor-managed data in IRT systems are creating avoidable compliance risk, particularly around investigational product inventory and quality actions.
Mohammed Najmul Hasan, MPharm
Advertisement
Clinical Trial Supply Manager, Novartis
Articles by Mohammed Najmul Hasan, MPharm
Advertisement
Latest Updated Articles
Clarifying Ownership of IRT Data in Clinical Trials: Distinguishing Investigator-Controlled Data from Sponsor Operational DataPublished: January 2nd 2026 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Evolution of Global Trial Strategies in Today's Complex Healthcare Landscape
2
ACT Brief: Global Trials Scale Up, Site-Centric Startup Gains Focus, and Pfizer Expands Vaccine Partnerships
3
Centering Site Experience to Accelerate Study Activation
4
ACT Brief: Life Sciences Hold the Line on DEI, Startup Timelines Stretch Further, and Regulators Align on AI Governance
5